MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clin...
Uloženo v:
| Vydáno v: | Current controlled trials in cardiovascular medicine Ročník 20; číslo 1; s. 263 - 13 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
09.05.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1745-6215, 1745-6215 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.
Methods/design
This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses.
Discussion
Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.
Trial registration
Andalusia:
NCT01745783
, registered on Dec 10, 2012.
Badalona:
NCT02035514
EudraCT, 2010–024081–21. Registered on 2012.
Canada: ClinicalTrials.gov,
NCT02239393
. Registered on September 12, 2014.
Copenhagen: EudraCT,
2012–000518-13
. Registered on June 21, 2012.
Italy: EudraCT, 2011–001295-19, and ClinicalTrials.gov,
NCT01854957
. Retrospectively registered on May 16, 2013.
London: Eudra CT 2012–002357-35, and ClinicalTrials.gov,
NCT01606215
. Registered on May 25, 2012.
Salzburg: EudraCT,
2015–000137-78
. Registered on September 15, 2015.
Stockholm: ClinicalTrials.gov,
NCT01730547
. Registered on November 21, 2012.
Toulouse: ClinicalTrials.gov,
NCT02403947
. Registered on March 31, 2015. |
|---|---|
| AbstractList | Background
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.
Methods/design
This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses.
Discussion
Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.
Trial registration
Andalusia:
NCT01745783
, registered on Dec 10, 2012.
Badalona:
NCT02035514
EudraCT, 2010–024081–21. Registered on 2012.
Canada: ClinicalTrials.gov,
NCT02239393
. Registered on September 12, 2014.
Copenhagen: EudraCT,
2012–000518-13
. Registered on June 21, 2012.
Italy: EudraCT, 2011–001295-19, and ClinicalTrials.gov,
NCT01854957
. Retrospectively registered on May 16, 2013.
London: Eudra CT 2012–002357-35, and ClinicalTrials.gov,
NCT01606215
. Registered on May 25, 2012.
Salzburg: EudraCT,
2015–000137-78
. Registered on September 15, 2015.
Stockholm: ClinicalTrials.gov,
NCT01730547
. Registered on November 21, 2012.
Toulouse: ClinicalTrials.gov,
NCT02403947
. Registered on March 31, 2015. Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS. Methods/design This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses. Discussion Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials. Trial registration Andalusia: NCT01745783, registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010-024081-21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393. Registered on September 12, 2014. Copenhagen: EudraCT, 2012-000518-13. Registered on June 21, 2012. Italy: EudraCT, 2011-001295-19, and ClinicalTrials.gov, NCT01854957. Retrospectively registered on May 16, 2013. London: Eudra CT 2012-002357-35, and ClinicalTrials.gov, NCT01606215. Registered on May 25, 2012. Salzburg: EudraCT, 2015-000137-78. Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547. Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947. Registered on March 31, 2015. Keywords: Multiple sclerosis, Mesenchymal stem cells, Mesenchymal stromal cells, Clinical trial Abstract Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS. Methods/design This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses. Discussion Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials. Trial registration Andalusia: NCT01745783, registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010–024081–21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393. Registered on September 12, 2014. Copenhagen: EudraCT, 2012–000518-13. Registered on June 21, 2012. Italy: EudraCT, 2011–001295-19, and ClinicalTrials.gov, NCT01854957. Retrospectively registered on May 16, 2013. London: Eudra CT 2012–002357-35, and ClinicalTrials.gov, NCT01606215. Registered on May 25, 2012. Salzburg: EudraCT, 2015–000137-78. Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547. Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947. Registered on March 31, 2015. BackgroundMultiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.Methods/designThis is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses.DiscussionResults will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.Trial registrationAndalusia: NCT01745783, registered on Dec 10, 2012.Badalona: NCT02035514 EudraCT, 2010–024081–21. Registered on 2012.Canada: ClinicalTrials.gov, NCT02239393. Registered on September 12, 2014.Copenhagen: EudraCT, 2012–000518-13. Registered on June 21, 2012.Italy: EudraCT, 2011–001295-19, and ClinicalTrials.gov, NCT01854957. Retrospectively registered on May 16, 2013.London: Eudra CT 2012–002357-35, and ClinicalTrials.gov, NCT01606215. Registered on May 25, 2012.Salzburg: EudraCT, 2015–000137-78. Registered on September 15, 2015.Stockholm: ClinicalTrials.gov, NCT01730547. Registered on November 21, 2012.Toulouse: ClinicalTrials.gov, NCT02403947. Registered on March 31, 2015. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS. This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses. Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials. Andalusia: NCT01745783 , registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010-024081-21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393 . Registered on September 12, 2014. Copenhagen: EudraCT, 2012-000518-13 . Registered on June 21, 2012. Italy: EudraCT, 2011-001295-19, and ClinicalTrials.gov, NCT01854957 . Retrospectively registered on May 16, 2013. London: Eudra CT 2012-002357-35, and ClinicalTrials.gov, NCT01606215 . Registered on May 25, 2012. Salzburg: EudraCT, 2015-000137-78 . Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547 . Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947 . Registered on March 31, 2015. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS. This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses. Trial registration Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.BACKGROUNDMultiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses.METHODS/DESIGNThis is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses.Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.DISCUSSIONResults will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.Andalusia: NCT01745783 , registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010-024081-21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393 . Registered on September 12, 2014. Copenhagen: EudraCT, 2012-000518-13 . Registered on June 21, 2012. Italy: EudraCT, 2011-001295-19, and ClinicalTrials.gov, NCT01854957 . Retrospectively registered on May 16, 2013. London: Eudra CT 2012-002357-35, and ClinicalTrials.gov, NCT01606215 . Registered on May 25, 2012. Salzburg: EudraCT, 2015-000137-78 . Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547 . Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947 . Registered on March 31, 2015.TRIAL REGISTRATIONAndalusia: NCT01745783 , registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010-024081-21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393 . Registered on September 12, 2014. Copenhagen: EudraCT, 2012-000518-13 . Registered on June 21, 2012. Italy: EudraCT, 2011-001295-19, and ClinicalTrials.gov, NCT01854957 . Retrospectively registered on May 16, 2013. London: Eudra CT 2012-002357-35, and ClinicalTrials.gov, NCT01606215 . Registered on May 25, 2012. Salzburg: EudraCT, 2015-000137-78 . Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547 . Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947 . Registered on March 31, 2015. |
| ArticleNumber | 263 |
| Audience | Academic |
| Author | Radue, Ernst W. Sormani, Maria Pia Laroni, Alice Soelberg Sorensen, Per Oliveri, Roberto S. Uccelli, Antonio Battaglia, Mario A. Nabavi, Seyed Massood Brundin, Lou Wuerfel, Jens Thomas Clanet, Michel Muraro, Paolo A. Sellner, Johann Fernandez, Oscar Freedman, Mark S. |
| Author_xml | – sequence: 1 givenname: Antonio orcidid: 0000-0002-2008-6038 surname: Uccelli fullname: Uccelli, Antonio email: auccelli@neurologia.unige.it organization: Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health and Center of Excellence for Biomedical Research (CEBR), University of Genova, IRCCS Ospedale Policlinico San Martino – sequence: 2 givenname: Alice surname: Laroni fullname: Laroni, Alice organization: Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health and Center of Excellence for Biomedical Research (CEBR), University of Genova, IRCCS Ospedale Policlinico San Martino – sequence: 3 givenname: Lou surname: Brundin fullname: Brundin, Lou organization: Karolinska Institutet, R3:04 Karolinska University Hospital 171 76 – sequence: 4 givenname: Michel surname: Clanet fullname: Clanet, Michel organization: CHU Toulouse, Université Paul Sabatier, INSERM UMR – sequence: 5 givenname: Oscar surname: Fernandez fullname: Fernandez, Oscar organization: Instituto de Investigación Biomédica de Málaga (IBIMA), Regional University Hospital of Malaga – sequence: 6 givenname: Seyed Massood surname: Nabavi fullname: Nabavi, Seyed Massood organization: Department of Brain and Cognitive Sciences, Royan Institute for Stem Cell Biology and Technology, ACCR, Iran and Regenerative Biomedicine Center, MS, Neurology Clinic and Research Unit – sequence: 7 givenname: Paolo A. surname: Muraro fullname: Muraro, Paolo A. organization: Department of Brain Sciences, Faculty of Medicine, Imperial College London – sequence: 8 givenname: Roberto S. surname: Oliveri fullname: Oliveri, Roberto S. organization: Cell Therapy Unit, Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet – sequence: 9 givenname: Ernst W. surname: Radue fullname: Radue, Ernst W. organization: Medical Image Analysis Centre Basel (MIAC AG) – sequence: 10 givenname: Johann surname: Sellner fullname: Sellner, Johann organization: Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University – sequence: 11 givenname: Per surname: Soelberg Sorensen fullname: Soelberg Sorensen, Per organization: Danish MS Center Department of Neurology, University of Copenhagen and Rigshospitalet – sequence: 12 givenname: Maria Pia surname: Sormani fullname: Sormani, Maria Pia organization: Department of Health Sciences, University of Genoa – sequence: 13 givenname: Jens Thomas surname: Wuerfel fullname: Wuerfel, Jens Thomas organization: Medical Image Analysis Centre Basel (MIAC AG), Department of Biomedical Engineering, University Basel – sequence: 14 givenname: Mario A. surname: Battaglia fullname: Battaglia, Mario A. organization: Italian Multiple Sclerosis Foundation, Department of Life Sciences, University of Siena – sequence: 15 givenname: Mark S. surname: Freedman fullname: Freedman, Mark S. organization: Department of Medicine (Neurology), University of Ottawa and the Ottawa Hospital Research Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31072380$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:140859060$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNp9U11v0zAUjdAQ-4AfwAuyxMuQyGbHsRPzgDRNBSqt4qHwbDn-aF2SuNjOpu7_8b9w15a1E6AosXPvOcf3Xt97mh31rtdZ9hrBC4RqehkQhhTnELEc45Lm98-yE1SVJKcFIkd7--PsNIQFhCVmuHyRHWMEqwLX8CT7NRkF3cv5qhMtmMZRB6Ru2wCM82AytNEuWw2mstXeBRvA-WQ0HU2m7z4AAbzolevsvVbvgXJDk4BNa_v0JxM45O5We7Cci6DB-HI8BjI5rUzHRG_T987GORBDdK2buSGATj8GEqLeDyTO9fr1YrkCzoBuF1fYxfUye25EG_Sr7XqWff80-nb9Jb_5-nl8fXWTS1qimJuKQUmkKhSrGgIJFbUhGgmmiTEFZahERtBaIFknn1CqbAQ0TNZImaIxDJ9l442ucmLBl952wq-4E5Y_GJyfceGjTWFxqWVTFqLBTY1KI6qGGqKE1KhUlCDaJK18oxXu9HJoDtS2ph9pp3lZMYZQwn_c4JOn00rqPnrRHtAOPb2d85m75ZTAChZVEjjfCnj3c9Ah8s6GdZFFr9MF8KLAiEFI6zpB3z6BLtzg-1RaXlSMYFrjEj-iZiIlbHvj0rlyLcqvSE0JYYjRhLr4Cyo9SndWpoY2NtkPCG_2E_2T4a5pE6DaAB76zGvDpY0iWrfO27YcQb4eD74ZD57Gg6_Hg98nJnrC3In_j1Ns7ylh-5n2j7X4N-k30iImUQ |
| CitedBy_id | crossref_primary_10_1016_j_msard_2023_104895 crossref_primary_10_3389_fcell_2021_772223 crossref_primary_10_3390_cells12162039 crossref_primary_10_1016_j_intimp_2024_112326 crossref_primary_10_1016_S1474_4422_21_00301_X crossref_primary_10_1096_fj_202001478R crossref_primary_10_3390_ijms221910542 crossref_primary_10_1016_j_rce_2023_10_002 crossref_primary_10_1186_s40001_025_02670_9 crossref_primary_10_1016_j_neurot_2025_e00601 crossref_primary_10_3389_ebm_2024_10055 crossref_primary_10_1016_j_autrev_2021_102873 crossref_primary_10_1097_TP_0000000000003765 crossref_primary_10_1080_14737175_2019_1632192 crossref_primary_10_1186_s13287_025_04254_0 crossref_primary_10_1016_j_molmed_2020_04_005 crossref_primary_10_3389_fcell_2020_00458 crossref_primary_10_1016_j_jcyt_2021_09_005 crossref_primary_10_1177_1352458520918377 crossref_primary_10_1186_s12883_021_02333_2 crossref_primary_10_3390_jcm9010241 crossref_primary_10_3390_ijms25126731 crossref_primary_10_1038_s41409_019_0684_0 crossref_primary_10_1007_s12015_021_10231_w crossref_primary_10_3390_ijms22073576 crossref_primary_10_1186_s13287_024_03885_z crossref_primary_10_1007_s11033_024_10057_y crossref_primary_10_1038_s41423_020_00618_z crossref_primary_10_1016_j_nbd_2022_105694 crossref_primary_10_1002_sctm_21_0021 crossref_primary_10_3390_ijms22105178 crossref_primary_10_1080_08830185_2023_2252007 crossref_primary_10_3389_fbioe_2023_1139359 crossref_primary_10_1007_s11064_019_02925_y crossref_primary_10_1089_scd_2020_0198 crossref_primary_10_1186_s12967_024_05450_x crossref_primary_10_3389_fnmol_2022_883378 crossref_primary_10_3390_ijms21030708 crossref_primary_10_3390_ijms22147536 crossref_primary_10_1016_j_jcyt_2021_12_004 crossref_primary_10_1016_j_rceng_2023_11_002 crossref_primary_10_1080_10790268_2021_1930369 crossref_primary_10_3390_biology14091130 crossref_primary_10_3390_cells12030348 crossref_primary_10_3389_fcell_2021_696434 crossref_primary_10_1155_2021_5583994 crossref_primary_10_1002_advs_202002944 crossref_primary_10_1016_j_msard_2022_103535 crossref_primary_10_1080_13543784_2020_1757647 crossref_primary_10_3390_jcm8122102 crossref_primary_10_3390_cells14151172 crossref_primary_10_3389_fneur_2024_1389697 crossref_primary_10_1177_13524585211060686 crossref_primary_10_3389_fneur_2024_1345503 crossref_primary_10_1007_s11010_024_05051_8 crossref_primary_10_3390_ijms23073829 crossref_primary_10_1186_s13287_024_03864_4 crossref_primary_10_1007_s12015_022_10369_1 crossref_primary_10_3390_biomedicines7030056 |
| Cites_doi | 10.1016/j.neuron.2018.01.021 10.1002/ana.21076 10.1016/j.imlet.2015.08.007 10.1002/stem.194 10.2174/157488812804484648 10.1001/archneur.65.6.753 10.1186/1745-6215-12-62 10.1371/journal.pone.0195891 10.1016/S0140-6736(18)30481-1 10.1016/S1474-4422(13)70103-0 10.1007/s11481-013-9456-6 10.1016/S0140-6736(08)60690-X 10.1177/1352458512464686 10.1016/j.jneuroim.2010.07.013 10.1016/S1474-4422(11)70121-1 10.1001/archneurol.2010.248 10.2217/rme-2016-0041 10.1056/NEJMoa052643 10.1182/blood-2005-04-1496 10.4049/jimmunol.0803962 10.1177/1352458509359727 10.1177/1352458509358090 10.1038/nn.3109 |
| ContentType | Journal Article |
| Contributor | Sormani, Maria Pia Blinkenberg, Morten Gimona, Mario Fernández, Óscar Rush, Carolina Ramo Tello, Cristina Oliveri, Roberto S Marrie, Ruth Ann Aguera-Morales, Eduardo Miller, David Dazzi, Francesco Szwajcer, David Marriott, James Nabavi, Seyed Massood Arab, Leila Comi, Giancarlo Wuerfel, Jens Thomas Izquierdo Ayuso, Guillermo Radue, Ernst W Sellner, Johann Clanet, Michel Bonetti, Bruno Nicholas, Richard Racosta, Juan Muraro, Paolo A Aghdami, Naser Rohde, Eva Freedman, Mark S Rabinovitch, H Laroni, Alice Introna, Martino Soelberg Sorensen, Per Uccelli, Antonio Battaglia, Mario A Karimi, Shahedeh Martino, Gianvito Brundin, Lou Ali, Rehiana Wall, Donna Herrera, Concepción MacLean, Heather Strunk, Dirk Vosoughi, Reza |
| Contributor_xml | – sequence: 1 givenname: Alice surname: Laroni fullname: Laroni, Alice – sequence: 2 givenname: Antonio surname: Uccelli fullname: Uccelli, Antonio – sequence: 3 givenname: Bruno surname: Bonetti fullname: Bonetti, Bruno – sequence: 4 givenname: Carolina surname: Rush fullname: Rush, Carolina – sequence: 5 givenname: Concepción surname: Herrera fullname: Herrera, Concepción – sequence: 6 givenname: Cristina surname: Ramo Tello fullname: Ramo Tello, Cristina – sequence: 7 givenname: David surname: Miller fullname: Miller, David – sequence: 8 givenname: David surname: Szwajcer fullname: Szwajcer, David – sequence: 9 givenname: Dirk surname: Strunk fullname: Strunk, Dirk – sequence: 10 givenname: Donna surname: Wall fullname: Wall, Donna – sequence: 11 givenname: Eduardo surname: Aguera-Morales fullname: Aguera-Morales, Eduardo – sequence: 12 givenname: Ernst W surname: Radue fullname: Radue, Ernst W – sequence: 13 givenname: Eva surname: Rohde fullname: Rohde, Eva – sequence: 14 givenname: Francesco surname: Dazzi fullname: Dazzi, Francesco – sequence: 15 givenname: Giancarlo surname: Comi fullname: Comi, Giancarlo – sequence: 16 givenname: Gianvito surname: Martino fullname: Martino, Gianvito – sequence: 17 givenname: Guillermo surname: Izquierdo Ayuso fullname: Izquierdo Ayuso, Guillermo – sequence: 18 givenname: H surname: Rabinovitch fullname: Rabinovitch, H – sequence: 19 givenname: Heather surname: MacLean fullname: MacLean, Heather – sequence: 20 givenname: James surname: Marriott fullname: Marriott, James – sequence: 21 givenname: Jens Thomas surname: Wuerfel fullname: Wuerfel, Jens Thomas – sequence: 22 givenname: Johann surname: Sellner fullname: Sellner, Johann – sequence: 23 givenname: Juan surname: Racosta fullname: Racosta, Juan – sequence: 24 givenname: Leila surname: Arab fullname: Arab, Leila – sequence: 25 givenname: Lou surname: Brundin fullname: Brundin, Lou – sequence: 26 givenname: Maria Pia surname: Sormani fullname: Sormani, Maria Pia – sequence: 27 givenname: Mario A surname: Battaglia fullname: Battaglia, Mario A – sequence: 28 givenname: Mario surname: Gimona fullname: Gimona, Mario – sequence: 29 givenname: Mark S surname: Freedman fullname: Freedman, Mark S – sequence: 30 givenname: Martino surname: Introna fullname: Introna, Martino – sequence: 31 givenname: Michel surname: Clanet fullname: Clanet, Michel – sequence: 32 givenname: Morten surname: Blinkenberg fullname: Blinkenberg, Morten – sequence: 33 givenname: Naser surname: Aghdami fullname: Aghdami, Naser – sequence: 34 givenname: Óscar surname: Fernández fullname: Fernández, Óscar – sequence: 35 givenname: Paolo A surname: Muraro fullname: Muraro, Paolo A – sequence: 36 givenname: Per surname: Soelberg Sorensen fullname: Soelberg Sorensen, Per – sequence: 37 givenname: Rehiana surname: Ali fullname: Ali, Rehiana – sequence: 38 givenname: Reza surname: Vosoughi fullname: Vosoughi, Reza – sequence: 39 givenname: Richard surname: Nicholas fullname: Nicholas, Richard – sequence: 40 givenname: Roberto S surname: Oliveri fullname: Oliveri, Roberto S – sequence: 41 givenname: Ruth Ann surname: Marrie fullname: Marrie, Ruth Ann – sequence: 42 givenname: Seyed Massood surname: Nabavi fullname: Nabavi, Seyed Massood – sequence: 43 givenname: Shahedeh surname: Karimi fullname: Karimi, Shahedeh |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | on behalf of the MESEMS study group MESEMS study group |
| CorporateAuthor_xml | – name: on behalf of the MESEMS study group – name: MESEMS study group |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTPV AOWAS D8T ZZAVC DOA |
| DOI | 10.1186/s13063-019-3346-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_cecb42ab3b814fa7b6f5dace14d6516b oai_swepub_ki_se_479911 PMC6507027 A586559196 31072380 10_1186_s13063_019_3346_z |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | Europe Italy Spain |
| GeographicLocations_xml | – name: Europe – name: Spain – name: Italy |
| GrantInformation_xml | – fundername: Paracelsus Medical University, Salzburg – fundername: Spinal Cord Injury and Tissue Regeneration Center Salzburg – fundername: Fondazione Italiana Sclerosi Multipla grantid: 2012/S/4 funderid: http://dx.doi.org/10.13039/100007366 – fundername: European Committee for Treatment and Research in Multiple Sclerosis funderid: http://dx.doi.org/10.13039/100008659 – fundername: The Toyota Foundation – fundername: Multiple Sclerosis Society grantid: 938/10 funderid: http://dx.doi.org/10.13039/501100000381 – fundername: Multiple Sclerosis International Federation funderid: http://dx.doi.org/10.13039/501100007459 – fundername: Danish Multiple Sclerosis Society – fundername: Danmarks Frivillige Bloddonorer (DK) – fundername: AFM-Téléthon funderid: http://dx.doi.org/10.13039/501100004923 – fundername: Fondazione Italiana Sclerosi Multipla grantid: 2012/S/4 – fundername: Multiple Sclerosis Society grantid: 938/10 – fundername: ; – fundername: ; grantid: 2012/S/4 – fundername: ; grantid: 938/10 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION -5E -5G -A0 -BR ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM 2VQ 4.4 ADTPV AHSBF AOWAS C1A D8T H13 IPNFZ RIG ZZAVC |
| ID | FETCH-LOGICAL-c641t-f790c5cd2d97b5056a8f5e1a9e5ff269141fa68a1c856aadd4ba0f9c81df2bf93 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 65 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000467610800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Fri Oct 03 12:28:32 EDT 2025 Tue Nov 25 03:32:48 EST 2025 Tue Nov 04 01:49:07 EST 2025 Fri Sep 05 12:58:00 EDT 2025 Sun Oct 19 01:43:58 EDT 2025 Tue Nov 11 10:05:16 EST 2025 Tue Nov 04 17:32:47 EST 2025 Thu Jan 02 22:59:40 EST 2025 Sat Nov 29 06:09:26 EST 2025 Tue Nov 18 21:30:03 EST 2025 Sat Sep 06 07:26:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Mesenchymal stromal cells Clinical trial Multiple sclerosis Mesenchymal stem cells |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c641t-f790c5cd2d97b5056a8f5e1a9e5ff269141fa68a1c856aadd4ba0f9c81df2bf93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0002-2008-6038 |
| OpenAccessLink | https://link.springer.com/10.1186/s13063-019-3346-z |
| PMID | 31072380 |
| PQID | 2795368343 |
| PQPubID | 44365 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_cecb42ab3b814fa7b6f5dace14d6516b swepub_primary_oai_swepub_ki_se_479911 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6507027 proquest_miscellaneous_2231900688 proquest_journals_2795368343 gale_infotracmisc_A586559196 gale_infotracacademiconefile_A586559196 pubmed_primary_31072380 crossref_citationtrail_10_1186_s13063_019_3346_z crossref_primary_10_1186_s13063_019_3346_z springer_journals_10_1186_s13063_019_3346_z |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-09 |
| PublicationDateYYYYMMDD | 2019-05-09 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | AJ Thompson (3346_CR1) 2018; 391 C Baecher-Allan (3346_CR3) 2018; 97 A Uccelli (3346_CR13) 2011; 10 K Le Blanc (3346_CR12) 2008; 371 E Gerdoni (3346_CR6) 2007; 61 G Constantin (3346_CR10) 2009; 27 A Uccelli (3346_CR22) 2013; 19 M Rafei (3346_CR8) 2009; 182 O Fernandez (3346_CR20) 2018; 13 P Connick (3346_CR17) 2011; 12 MP Sormani (3346_CR25) 2013; 12 E Zappia (3346_CR5) 2005; 106 Z Khaleeli (3346_CR2) 2010; 16 Lianhua Bai (3346_CR11) 2012; 15 L Kappos (3346_CR23) 2006; 355 MS Freedman (3346_CR21) 2010; 16 B Yamout (3346_CR15) 2010; 227 MM Bonab (3346_CR18) 2012; 7 D Karussis (3346_CR16) 2010; 67 J Correale (3346_CR4) 2017; 140 Alice Laroni (3346_CR19) 2013; 8 M Mohyeddin Bonab (3346_CR14) 2007; 4 G Martino (3346_CR24) 2016; 11 I Kassis (3346_CR7) 2008; 65 A Laroni (3346_CR9) 2015; 168 |
| References_xml | – volume: 97 start-page: 742 year: 2018 ident: 3346_CR3 publication-title: Neuron doi: 10.1016/j.neuron.2018.01.021 – volume: 61 start-page: 219 year: 2007 ident: 3346_CR6 publication-title: Ann Neurol doi: 10.1002/ana.21076 – volume: 168 start-page: 183 year: 2015 ident: 3346_CR9 publication-title: Immunol Lett doi: 10.1016/j.imlet.2015.08.007 – volume: 27 start-page: 2624 year: 2009 ident: 3346_CR10 publication-title: Stem Cells doi: 10.1002/stem.194 – volume: 7 start-page: 407 year: 2012 ident: 3346_CR18 publication-title: Curr Stem Cell Res Ther doi: 10.2174/157488812804484648 – volume: 65 start-page: 753 year: 2008 ident: 3346_CR7 publication-title: Arch Neurol doi: 10.1001/archneur.65.6.753 – volume: 12 start-page: 62 year: 2011 ident: 3346_CR17 publication-title: Trials doi: 10.1186/1745-6215-12-62 – volume: 13 start-page: e0195891 year: 2018 ident: 3346_CR20 publication-title: PLoS One doi: 10.1371/journal.pone.0195891 – volume: 391 start-page: 1622 year: 2018 ident: 3346_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(18)30481-1 – volume: 4 start-page: 50 year: 2007 ident: 3346_CR14 publication-title: Iran J Immunol – volume: 12 start-page: 669 year: 2013 ident: 3346_CR25 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(13)70103-0 – volume: 8 start-page: 1062 issue: 5 year: 2013 ident: 3346_CR19 publication-title: Journal of Neuroimmune Pharmacology doi: 10.1007/s11481-013-9456-6 – volume: 371 start-page: 1579 year: 2008 ident: 3346_CR12 publication-title: Lancet doi: 10.1016/S0140-6736(08)60690-X – volume: 19 start-page: 515 year: 2013 ident: 3346_CR22 publication-title: Mult Scler doi: 10.1177/1352458512464686 – volume: 227 start-page: 185 year: 2010 ident: 3346_CR15 publication-title: J Neuroimmunol doi: 10.1016/j.jneuroim.2010.07.013 – volume: 10 start-page: 649 year: 2011 ident: 3346_CR13 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70121-1 – volume: 67 start-page: 1187 year: 2010 ident: 3346_CR16 publication-title: Arch Neurol doi: 10.1001/archneurol.2010.248 – volume: 11 start-page: 347 year: 2016 ident: 3346_CR24 publication-title: Regen Med doi: 10.2217/rme-2016-0041 – volume: 140 start-page: 527 year: 2017 ident: 3346_CR4 publication-title: Brain – volume: 355 start-page: 1124 year: 2006 ident: 3346_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMoa052643 – volume: 106 start-page: 1755 year: 2005 ident: 3346_CR5 publication-title: Blood doi: 10.1182/blood-2005-04-1496 – volume: 182 start-page: 5994 year: 2009 ident: 3346_CR8 publication-title: J Immunol doi: 10.4049/jimmunol.0803962 – volume: 16 start-page: 503 year: 2010 ident: 3346_CR21 publication-title: Mult Scler doi: 10.1177/1352458509359727 – volume: 16 start-page: 317 year: 2010 ident: 3346_CR2 publication-title: Mult Scler doi: 10.1177/1352458509358090 – volume: 15 start-page: 862 issue: 6 year: 2012 ident: 3346_CR11 publication-title: Nature Neuroscience doi: 10.1038/nn.3109 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.4611475 |
| Snippet | Background
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability.... Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal... Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability.... BackgroundMultiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability.... Abstract Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible... |
| SourceID | doaj swepub pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 263 |
| SubjectTerms | Adolescent Adult Analysis Biomedicine Business financing Care and treatment Central nervous system Clinical trial Clinical trials Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Cross-Over Studies Data collection Diagnostic imaging Disability Evaluation Double-Blind Method Double-blind studies Europe Female Good Manufacturing Practice Health Sciences Humans Inflammation Magnetic Resonance Imaging Male Medical research Medicine Medicine & Public Health Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal stem cells Mesenchymal stromal cells Middle Aged Multicenter Studies as Topic Multiple sclerosis Multiple Sclerosis - diagnostic imaging Multiple Sclerosis - physiopathology Multiple Sclerosis - surgery Nonprofit organizations Randomized Controlled Trials as Topic Recovery of Function Statistics for Life Sciences Stem cell transplantation Stem cells Study Protocol Time Factors Transplantation, Autologous Treatment Outcome Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1da9swUIwyxl7Guk9v3dBg7NvEsmVZ2ls3UpaHlEE26JuQZImELkmpk0Lz__a_duePNO6ge9lbbJ3ISfdtne4IeS1VClTnWSwgWo55DgGrkSmLsakDM6KEECCpm00Ux8fy5ER932n1hTlhTXngZuMGzjvLU2MzKxkPprAi5KVxnvFS5ExY1L5JobpgqtHBYGUz3p5hMikGFWhqPK9kKs4yLuJNzwrVxfr_Vsk7Nul6vuT20PRagdHaKB3dJ_dab5IeNqvYJ7f84gG5M27Pyx-S3-NhBWw4vZwD1GQ1nFP8UF9R8FTpuE0lpBOYCljOKvpuPJwMx5P3n6mhYMPK5Xy28eUnWi7XFgAtuKTwVC8pxtRPejYFI0hHg9GIdlcsad0HhOL3XWrWdXfc5bqic3-FCNaO3kEEXFDaXAO7pMtAuxRHWnV4PSI_j4Y_vn6L28YNsROcreJQqMTlrkxLVVh0sYwMuWdG-TyEVCjGWTBCGuYkjIGG5dYkQTnwnUNqg8oek73FcuGfEupcmXmA8z43PChlsNyOkKB2BPee24gkHSG1a6uaY3ONX7qObqTQDe010F4j7fUmIh-2U86akh43AX9B7tgCYjXu-gXwqG55VP-LRyPyFnlLo84A5Jxprz7AErH6lj7M8XqwAmUYkYMeJMi66w933KlbXVNpELY8ExIELiKvtsM4E_PnFh6IrMEJBM8PGwxF5EnDzNslgYOPneeSiBQ9Nu-tuT-ymE3rSuTg3hdJWkTkYycQV2jdsKVvGpnp_UH76hR-ec0LCFvYs_-x98_J3RTlHnNU1QHZW52v_Qty212sZtX5y1pr_AGqmHU5 priority: 102 providerName: Directory of Open Access Journals – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgQYgL70dgQUZCvKPGiePEXNCCuqKHrhAFtDfLcRxaQZvStEjb_8f_YiZx0s0i7YVbG4-TmWT8ecYezxDyNJUhfHUe-QK8ZZ_H4LDqNGQ-FnVgWuTgAgR1sYnk6Cg9Ppaf3IJb5cIqW0ysgTovDa6RD-CWcSRSuO275S8fq0bh7qoroXGRXGJoG4M-J5-_dbsISSq428lkqRhUgNe4a8mkH0Vc-NveXFSn7P8XmE_NTGejJrut0zNpRuup6fD6_wp1g1xzRik9aLToJrlgF7fIlbHbdr9N_oyHFWjz9GQOVJP1cE5xvb-iYPDSsYtIpBPoCmLOKvpiPJwMx5OXb6mmMBXm5Xy2tfkbmpebDAgzsGzhX_1OfIwgpcspzKV0NBiNaHtSk9blRCguE1O9qYvslpuKzu2OEUxBfYoRsGRpc5rshJYFbSMladXydYd8PRx--fDRd_UffCM4W_tFIgMTmzzMZZKhpabTIrZMSxsXRSgk46zQItXMpNAGQM0zHRTSgAlehFkho7tkb1Eu7H1CjckjC3TWxpoXUmrM2iNSQC_BreWZR4JWE5RxydGxRsdPVTtJqVCN8ihQHoXKo7YeedV1WTaZQc4jfo_q1RFiUu_6Qrn6rhxGKGNNxkOdRVnKeKGTTBRxro1lPBcxE8Dkc1ROhdADzBntTlCAiJjESx3EeMpYAqZ6ZL9HCZBh-s2tOioHWZXa6aJHnnTN2BPD8BYWPrICWxIMSKxT5JF7zWjoRAI_AQvYBR5JeuOkJ3O_ZTGb1gnNwUtIgjDxyOt2RO3YOueVPmsGXe8B7tIP-GUVT8D7YQ_Ol_YhuRoiJGAQq9wne-vVxj4il83v9axaPa4B5S_AtIGr priority: 102 providerName: ProQuest |
| Title | MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis |
| URI | https://link.springer.com/article/10.1186/s13063-019-3346-z https://www.ncbi.nlm.nih.gov/pubmed/31072380 https://www.proquest.com/docview/2795368343 https://www.proquest.com/docview/2231900688 https://pubmed.ncbi.nlm.nih.gov/PMC6507027 http://kipublications.ki.se/Default.aspx?queryparsed=id:140859060 https://doaj.org/article/cecb42ab3b814fa7b6f5dace14d6516b |
| Volume | 20 |
| WOSCitedRecordID | wos000467610800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1rb9Mw0GIbQnzh_QiMykiId7Q8HMfm24Yy0Q-pqham8slyHIdW0GZqWqT1__G_ODtJtww0Cb5ETXxOzznfyz7fIfSC8QCoTkKXgrfskggcVskC3zVFHXxJc3ABPFtsIh4M2GTCh8057qqNdm-3JK2ktmzN6EEF0tbsOfrcDUNC3c0O2gNtx0y9htH4pBW_oGBD0mxf_rVbRwHZPP1_SuML6uhyqOR2v_RSblGrj45v_9dI7qBbjfmJD-v5chdd04t76EbabLDfR7_SpIJ5Oz2bA9R4lcyxWdmvMJi2OG1iD_EYusLYZhV-nSbjJB2_-YAlBqWXl_PZRufvcV6uMwDMADu4sx_CNbGi-HQKWhP3D_p93J7JxLZwCDYLwliubTndcl3huT5HxCSbvoAI2Ky4Pjd2hssCtzGRuGrxeoC-HCefP35ym0oPrqLEX7lFzD0VqTzIeZwZm0yyItK-5DoqioByn_iFpEz6ikEbiGSSSa_gCoztIsgKHj5Eu4tyoR8jrFQeaoDTOpKk4Fya_DyUgZyiRGuSOchryS9UkwbdVOP4Iaw7xKioySOAPMKQR2wc9Hbb5bTOAXIV8JGZU1tAk77bPiiX30QjDYTSKiOBzMKM-aSQcUaLKJdK-ySnkU8ByVdmRgojZAA5JZuzEjBEk65LHEbmPDEH6emg_Q4kCAfVbW7ntGiEUyWAO6OQMuBQBz3fNpueJuBuoYHIAqxGMBVNRSIHPapZYDsk8AhMqTrPQXGHOTpj7rYsZlObuhz8gdgLYge9aznjHK0rPunLmtM6f9A8-g6_tCAx-Dn-k3967VN0MzA8aKJX-T7aXS3X-hm6rn6uZtWyh3bi0Ym5TmJ7ZT20d5QMhqOeXbaBu2E_HX7tWeHzGz2sfs4 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3ZjtMw0FotCHjhPgILGIkbotap4yRICC3Q1Va7WSF1kfpmHMehFbQpTQtqP4q_4L-YydXNIvVtH3hL4nEytueMxzOEPPYDB1add2wB3rLNXXBYle8wG4s6MCVicAHaebEJ7-jIHwyCT1vkd3UWBsMqK5mYC-o41fiPvAWvdDvCh9e-m_6wsWoU7q5WJTQKsjgwy1_gsmVvex9hfZ84zl73-MO-XVYVsLXgbG4nXtDWro6dOPAi1P_KT1zDVGDcJHFEwDhLlPAV0z60AfvzSLWTQINhlzhRgsmXQOSfAznuobPnDWoHj3m-4OXOKfNFKwP9gLukLLA7HS7sVUP35SUC_lUEJzTh6SjNeqv2VFrTXBXuXfnfJvEquVwa3XS34JJrZMtMrpMLYRlWcIP8CbsZcOtwOQao_rw7prifkVEw6GlYRlzSPnSFaR1l9HnY7XfD_os3VFFQ9XE6Hq1M_JrG6SICwAgsd7jL18DGCFk6HYKtQHutXo9WJ1FpXi6F4m9wqhZ5EeF0kdGxWSOCKbZPIAKWOi1Oyy1pmtAqEpRmFV43yeczmcRbZHuSTswdQrWOOwbgjHEVT4JAYVYi4YN0FtwYHlmkXVGe1GXyd6xB8l3mTqAvZEGsEohVIrHKlUVe1l2mReaTTcDvkZxrQExanj9IZ19lKQOlNjrijoo6kc94orxIJG6stGE8Fi4TgOQzZAaJohWQ06o8IQJDxCRlctfFU9QB6AyL7DQgQSTqZnNF_rIUyZlc075FHtXN2BPDDCcGFlmCrQwGMtZhssjtgvvqIYEfhAX62hbxGnzZGHOzZTIa5gnbwQvy2o5nkVcVB6_R2jClTwsmb3ygfPQNrozkHnh37O7m0T4kF_ePw0N52Ds6uEcuOSiOMGA32CHb89nC3Cfn9c_5KJs9yIUZJV_OmvH_Al-54RM |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R1db9Mw0Jo2NPHC90dggJH4hqh16jgJEkKDdaIanSp1SOPJOI5NK2hTmhbU_jTe-V_c5aNdhrS3PfDWxpfkbN9n7nxHyKMw8mDXecsV4C273AeHVYUec7GpA1MiARegmTebCA4Pw-PjqLdBfldnYTCtspKJuaBOUo3fyBvwSL8lQnhsw5ZpEb29_beTHy52kMJIa9VOoyCRA7P4Be5b9qazB3v92PP220fvP7hlhwFXC85mrg2ipvZ14iVREKMtoELrG6Yi41vriYhxZpUIFdMhjIEo4LFq2kiDkWe92GIhJhD_W2CSc2-TbPU63d7nVQwjCAUv46gsFI0MtAXGTFnktlpcuMuaJswbBvyrFk7oxdM5m6vA7akip7li3L_8Py_pFXKpNMfpbsE_V8mGGV8j290y4eA6-dNtZ8DHg8UIoPqz9ohipCOjYOrTbpmLSftwKyzxMKPPuu1-u9t__poqCkZAko6GS5O8okk6jwEwBpse_uX74WLuLJ0MwIqgnUanQ6szqjRvpELxAzlV87y9cDrP6MisEcHi2ycQARueFufoFjS1tMoRpVmF1w3y6VwW8SbZHKdjc5tQrZOWAThjfMVtFCmsVyRCkNuCG8NjhzQrKpS6LAuP3Um-y9w9DIUsCFcC4UokXLl0yIvVLZOiJspZwO-QtFeAWM48v5BOv8pSOkptdMw9FbfikHGrglhYP1HaMJ4InwlA8ikyhkShC8hpVZ4dgSli-TK56-P56gi0iUN2apAgLHV9uGIFWQrrTK75wCEPV8N4JyYgjg1ssgQrGkxn7NDkkFsFJ66mBB4Stu5rOiSo8WhtzvWR8XCQl3IH_yhoeoFDXlbcvEbrjCV9UjB87QXlpW_wy0gegN_H7pw92wdkG_hdfuwcHtwlFz2UTJjJG-2Qzdl0bu6RC_rnbJhN75eSjZIv5835fwHBtOti |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MEsenchymal+StEm+cells+for+Multiple+Sclerosis+%28MESEMS%29%3A+a+randomized%2C+double+blind%2C+cross-over+phase+I%2FII+clinical+trial+with+autologous+mesenchymal+stem+cells+for+the+therapy+of+multiple+sclerosis&rft.jtitle=Trials&rft.au=Uccelli%2C+Antonio&rft.au=Laroni%2C+Alice&rft.au=Brundin%2C+Lou&rft.au=Clanet%2C+Michel&rft.date=2019-05-09&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-019-3346-z&rft.externalDocID=10_1186_s13063_019_3346_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |